Table of contents


On 22 February 2018, orphan designation (EU/3/18/1985) was granted by the European Commission to Raremoon Consulting Ltd, United Kingdom, for rusalatide acetate (also known as TP508) for the treatment of acute radiation syndrome.

Key facts

Active substance
Rusalatide acetate
Disease / condition
Treatment of acute radiation syndrome
Date of decision
Orphan decision number

Sponsor's contact details

Raremoon Consulting Ltd
International House
24 Holborn Viaduct
City of London
London EC1A 2BN
Tel. +44 203 5145553

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating